Pfizer offshoot Zoetis enjoys stock surge after IPO

Stock for Pfizer's ($PFE) animal health spinoff Zoetis ($ZTS) soared 21% after raising more than $2.2 billion in its initial public offering. Shares went for $31 apiece this morning after selling for $26 each yesterday, above Pfizer's proposed offering range of $22 to $25. The biggest IPO since Facebook, Pfizer offered up about 17% of Zoetis. Yesterday, Zoetis sold 86.1 million shares, according to Bloomberg. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.